Pliant Therapeutics Files 2025 Proxy Statement
Ticker: PLRX · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: PLRX
TL;DR
PLRX proxy out - exec comp details for 2024, equity award values disclosed.
AI Summary
Pliant Therapeutics, Inc. filed its DEF 14A on April 23, 2025, detailing executive compensation and other corporate matters for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to its "PeoMember" (likely principal executive officer) in prior years and the year-end fair value of outstanding and unvested equity awards.
Why It Matters
This filing provides shareholders with crucial information regarding executive compensation, which can influence investor decisions and company governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing (DEF 14A) that primarily discloses executive compensation and corporate governance information, not material operational or financial changes.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation details.)
- 2023 — Fiscal Year End (Previous fiscal year for comparative compensation data.)
- 2022 — Fiscal Year End (Prior fiscal year for compensation data.)
- 2021 — Fiscal Year End (Earlier fiscal year for compensation data.)
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Filer
- 0001746473-25-000089 (filing_id) — Accession Number
- 20250423 (date) — Filing Date
- 20250605 (date) — Period of Report
- 331 OYSTER POINT BOULEVARD (address) — Business Address
- SOUTH SAN FRANCISCO (location) — Business Address City
- CA (location) — Business Address State
- 94080 (zip_code) — Business Address Zip
- 650-481-6770 (phone_number) — Business Phone
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the company's annual meeting, including details on executive compensation, director nominations, and other corporate governance matters.
When is the fiscal year end for Pliant Therapeutics, Inc. as stated in the filing?
The fiscal year end for Pliant Therapeutics, Inc. is December 31st, as indicated by the reporting periods for 2021, 2022, 2023, and 2024.
What type of equity awards are detailed in the filing?
The filing details equity awards granted to "PeoMember" (likely Principal Executive Officer) and includes information on the year-end fair value of outstanding and unvested equity awards.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 23, 2025.
What is the Standard Industrial Classification (SIC) code for Pliant Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Pliant Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding PLIANT THERAPEUTICS, INC. (PLRX).